Stage III Breast Cancer Recruiting Phase 1 / 2 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0031775 (Stage III Breast Cancer)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03106415Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast CancerTreatment